Cite

HARVARD Citation

    Garcia, C. et al. (2016). Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer. Cancer investigation. pp. 521-530. [Online]. 
  
Back to record